Small crises become larger crises when systems meant to prevent them collapse
In the northeastern provinces of the Democratic Republic of the Congo, a strain of Ebola for which no vaccine exists has claimed more than 180 lives among over 800 reported cases, prompting the WHO to declare a global health emergency. The Bundibugyo virus has found its footing in a landscape already hollowed out by decades of armed conflict, collapsed health infrastructure, and the sudden withdrawal of international aid. This is not merely a medical crisis but a reckoning with what happens when the systems built to prevent catastrophe are dismantled before the catastrophe arrives.
- The WHO bypassed its usual advisory process to declare an international emergency, signaling that the scale and speed of this outbreak demanded a response faster than protocol allows.
- No approved vaccine exists for Bundibugyo virus — the shots the world stockpiled were engineered for a different Ebola strain, and manufacturing a new one could take six to nine months the outbreak does not have.
- Diagnosis is slow and unreliable, early symptoms are indistinguishable from common illnesses, and the regions hardest hit are fragmented by armed conflict and controlled in parts by a rebel group, making coordinated containment nearly impossible.
- A 70 percent cut in humanitarian aid following the closure of USAID has shuttered clinics, laid off health workers, and drained the very infrastructure that would normally absorb and contain an outbreak like this.
- Two cases have already crossed into Uganda and one American was evacuated to Germany, confirming that the virus is not contained within DRC's borders and that international spread is a live risk, not a distant one.
On May 19, the World Health Organization declared a public health emergency of international concern after more than 800 people in the Democratic Republic of the Congo contracted Ebola and at least 180 died. The strain driving the outbreak was not the one the world had prepared for. It was Bundibugyo virus — a relative of the better-known Zaire ebolavirus — and it arrived in a region where the systems meant to stop it had already been gutted.
The outbreak likely began in late April, possibly amplified by a superspreader event at a funeral or healthcare facility. Cases spread across northeastern provinces and crossed into Uganda. One American was evacuated to Germany. WHO Director-General Tedros Adhanom Ghebreyesus acted without convening his usual advisory committee, citing the epidemic's scale and speed.
The pharmaceutical problem was immediate: the approved Ebola vaccines target Zaire ebolavirus specifically, sharing only 60 to 70 percent of its genetic material with Bundibugyo. Cross-protection is minimal. An experimental Bundibugyo vaccine exists but no doses have been manufactured, and producing them would take six to nine months. A second candidate might be ready in two to three months, but animal trials are unfinished. Without vaccines, responders were left with the oldest tools — find cases, isolate them, enforce infection control — in conditions that made each step harder than the last.
Diagnosis compounded the difficulty. Bundibugyo's early symptoms mirror dozens of other illnesses, PCR tests for the specific strain are scarce, and the virus takes days to become detectable even after symptoms appear. Rapid tests may miss it entirely. There are no approved antiviral treatments either — antibody therapies that improve survival in Zaire ebolavirus cases have no equivalent for Bundibugyo.
The outbreak's epicenter, Ituri province, has endured armed conflict for decades. Cases have also emerged in North and South Kivu, parts of which are controlled by the Rwanda-backed rebel group M23, fracturing any unified response. Displaced residents shelter in crowded schools and churches with little access to clean water or healthcare — conditions that are, in effect, ideal for Ebola transmission.
Funding collapse deepened every vulnerability. The closure of USAID stripped eastern DRC of roughly 70 percent of its humanitarian aid. Clinics shuttered, health workers were laid off, and supply chains collapsed. Oxfam's DRC country director was precise about the consequence: funding cuts don't cause outbreaks, but they destroy the systems that keep small crises from becoming large ones.
Trust, too, is fractured. During the 2018-2020 outbreak in North Kivu, international responders sidelined local health systems, breeding suspicion that has not fully healed. Communities continue traditional burial practices that carry transmission risk, and persuading people to change behavior is harder when they have watched aid disappear and hospitals close.
The outbreak remains concentrated in the DRC, but the WHO has flagged a high risk of international spread. Whether it stays contained depends on whether resources, coordination, and political will arrive before the virus moves faster than the response.
The World Health Organization declared a public health emergency of international concern on May 19, and the reason was stark: more than 800 people in the Democratic Republic of the Congo had contracted Ebola, and at least 180 of them were dead. The virus spreading through the northeastern provinces wasn't the strain the world had prepared for. It was Bundibugyo virus, a relative of the more infamous Zaire ebolavirus, and it arrived in a place where the systems meant to stop it were already broken.
The outbreak likely began around late April, when someone died from what officials now believe was Bundibugyo infection. A superspreader event—possibly at a funeral or a healthcare facility—accelerated transmission. Two cases crossed into Uganda among travelers from the DRC, and one American contracted the virus and was evacuated to Germany for treatment. The WHO director-general, Tedros Adhanom Ghebreyesus, moved without convening his usual advisory committee. "The scale and speed of the epidemic demanded urgent action," he said. The agency anticipated rapid international spread.
The first problem was pharmaceutical: there is no vaccine for Bundibugyo virus. The approved Ebola vaccines exist, but they were engineered specifically to target Zaire ebolavirus, which caused the massive 2014-2016 outbreak. The two viruses share only 60 to 70 percent of their genetic material. The vaccines work by training the immune system to recognize a specific protein, and that protein's genetic code differs between the two strains. Cross-protection is minimal. Dr. Madeline DiLorenzo, a clinical coordinator of infectious diseases at NYU Langone's Tisch Hospital, explained that immune responses to these viruses are narrowly focused—the body learns to fight one type, not both. An experimental Bundibugyo vaccine exists, but no doses are manufactured. The WHO estimates it would take six to nine months to produce them. Another candidate in development could be ready in two to three months, but its effectiveness remains unknown because animal trials haven't finished.
Without a vaccine, the standard containment strategies—ring vaccination of exposed contacts, or geographic vaccination of entire outbreak zones—were unavailable. Clinicians had to rely on what remained: finding cases, isolating them, and enforcing strict infection control. But diagnosis itself was a barrier. Bundibugyo virus causes generic early symptoms—fever, fatigue, muscle pain, headache, sore throat—that appear two to 21 days after exposure. PCR tests that detect the virus's genetic material exist but are not widely available for Bundibugyo. Even when available, the virus takes several days to become detectable in blood after symptoms start, requiring repeat testing. Rapid diagnostic tests that look for viral proteins are less sensitive and may miss Bundibugyo entirely. Dr. Jill Weatherhead, an associate professor of infectious disease at Baylor College of Medicine, noted that these diagnostic gaps "may have contributed to delayed detection of the current outbreak." There are no specific antiviral treatments for Bundibugyo either. Lab-made antibodies approved for Zaire ebolavirus improve survival rates, but similar treatments for Bundibugyo haven't progressed beyond early research.
The deepest problem was geography and politics. The outbreak's epicenter is Ituri province in the northeastern DRC, a region that has endured armed conflict for decades. The health system there is severely compromised. Cases have also appeared in North and South Kivu provinces, parts of which are controlled by the Rwanda-backed rebel group M23, fragmenting any unified response. Violence among armed groups in Ituri has intensified recently. Residents have been repeatedly displaced by conflict and now shelter in crowded schools and churches with minimal access to clean water, sanitation, or healthcare. Ebola spreads through contact with infected blood and bodily fluids, and these conditions are ideal for transmission.
Funding collapse made everything worse. The U.S. Agency for International Development, the main donor supporting healthcare in the DRC, was shut down last year. Eastern DRC lost approximately 70 percent of its humanitarian aid as a result. Other donors cut funding afterward. Medical centers closed. Medical supplies dwindled. Community health workers were laid off. The capacity to respond to outbreaks evaporated. Dr. Manenji Mangundu, DRC country director for Oxfam, which is coordinating ground-level response efforts, was direct: "Funding cuts directly do not cause outbreaks, but they do weaken the very systems that are meant to prevent small crises from becoming larger crises."
There is another layer of difficulty: trust. During the 2018-2020 Ebola outbreak in North Kivu, the international response sidelined local Congolese health systems, viewing them as too weak to be effective partners. Outside organizations orchestrated the response, which bred suspicion in affected communities. Joshua Walker, director of programs at the Congo Research Group at NYU's Center on International Cooperation, noted that "one hopes there have been some hard lessons learned by the international community since the last major outbreak." But the structural problems remain. Communities continue to handle the bodies of deceased relatives as part of their traditions, increasing transmission risk. Convincing people to change these practices is harder when they have seen aid disappear and health infrastructure collapse.
Mangundu's final message was a warning wrapped in a plea: "There is capacity in the country to respond, but there are not enough resources to help control and prevent the spread. We need to fund humanitarian aid and support the people of DRC at this time before a preventable crisis turns into one with far wider, global consequences." The outbreak is still concentrated in the DRC, but the WHO has flagged a high risk of international spread. What happens next depends on whether the world acts before the virus does.
Notable Quotes
The scale and speed of the epidemic demanded urgent action— WHO Director-General Tedros Adhanom Ghebreyesus
Funding cuts directly do not cause outbreaks, but they do weaken the very systems that are meant to prevent small crises from becoming larger crises— Dr. Manenji Mangundu, DRC country director for Oxfam
The Hearth Conversation Another angle on the story
Why is Bundibugyo virus so much harder to contain than the Zaire strain we've dealt with before?
It's not that Bundibugyo is inherently more dangerous—it's that we built our defenses for Zaire. The vaccines, the antibody treatments, the diagnostic protocols—all of it was engineered for a virus that shares only 60 to 70 percent of its genetic code with Bundibugyo. The immune system doesn't cross over. We're essentially fighting with last war's weapons.
But couldn't they just make a Bundibugyo vaccine quickly?
That's the cruel part. An experimental vaccine exists, but manufacturing it takes six to nine months. We're in May. Even if they started tomorrow, we wouldn't have doses until late fall. By then, the outbreak could have spread far beyond the DRC.
So they're relying on the old methods—isolation, contact tracing, infection control?
Yes, but those methods require a functioning health system. Ituri province has been at war for decades. Health centers are closing, not opening. Community health workers are being laid off because USAID was shut down and took 70 percent of the region's humanitarian aid with it.
How does conflict specifically make this worse?
Conflict displaces people into crowded shelters—schools, churches—with no clean water or sanitation. Ebola spreads through bodily fluids. You put hundreds of displaced people in a church with one water source, and the virus moves through them like fire. And the armed groups fragmenting the territory mean there's no single coordinated response.
Is there any reason for hope?
The outbreak is still concentrated in the DRC. If the international community acts now—funds the response, supports local health systems instead of sidelining them—there's still time. But every week of delay, every funding cut, every armed group skirmish makes that window smaller.
What would "acting now" actually look like?
Money, first. Restore the humanitarian aid that was cut. Support the health workers and clinics that are still functioning. Work with local communities instead of imposing solutions from outside. And pray the experimental vaccines can be manufactured faster than anyone expects.